Displaying 1 - 12 of 16
Immune-Mediated and Cholestatic Diseases
6

Intercept: Providing Better Care in PBC – understanding the evolving evidence - ILC 2021

View
Immune-Mediated and Cholestatic Diseases
6

Intercept: Providing Better Care in PBC – understanding the evolving evidence - ILC 2021

View
Immune-Mediated and Cholestatic Diseases
6

Intercept: Providing Better Care in PBC – understanding the evolving evidence - ILC 2021

View
Immune-Mediated and Cholestatic Diseases
6

Intercept: Providing Better Care in PBC – understanding the evolving evidence - ILC 2021

View
Immune-Mediated and Cholestatic Diseases
6

Intercept: Providing Better Care in PBC – understanding the evolving evidence - ILC 2021

View
Immune-Mediated and Cholestatic Diseases
6

Intercept: Providing Better Care in PBC – understanding the evolving evidence - ILC 2021

View
Metabolism, Alcohol & Toxicity
4

Intercept: Emerging trends in the care pathway for patients with NASH - Digital ILC 2020

View
Metabolism, Alcohol & Toxicity
4

Intercept: Emerging trends in the care pathway for patients with NASH - Digital ILC 2020

View
Metabolism, Alcohol & Toxicity
4

Intercept: Emerging trends in the care pathway for patients with NASH - Digital ILC 2020

View
Metabolism, Alcohol & Toxicity
4

Intercept: Emerging trends in the care pathway for patients with NASH - Digital ILC 2020

View
General Hepatology
6

Intercept: FXR agonism in clinical practice: new perspectives from the real-world experience in PBC - Digital ILC 2020

View
General Hepatology
6

Intercept: FXR agonism in clinical practice: new perspectives from the real-world experience in PBC - Digital ILC 2020

View
Displaying 1 - 12 of 16